Zera Health review

Separate the opening offer from the monthly plan

Zera Health lists a semaglutide monthly plan at $179, above an advertised first-month floor of $149. Tirzepatide is $255 on the monthly plan, while its opening floor is $199. The dedicated product pages provide a more useful ongoing comparison than the older homepage starting figures. Ask which dose, formulation, and quantity qualify and what the next refill costs. A first payment and a regular plan charge should remain separate even when they appear near each other.

Tirzepatide also has a quarterly option advertised at $215 per month, billed every three months. That implies a larger term purchase rather than an independently cancellable $215 payment each month; obtain the actual total and authorization before agreeing. The selected supply and prescription should be identified alongside that schedule. A lower average can help compare commitments, but it does not establish that the clinical plan will remain unchanged throughout a prepaid period or that unused treatment will be refundable.

The $99 banner belongs to a broader catalog

Zera's site-wide marketing uses a starting figure of $99, but the weight-management offers have different product-specific prices. NAD+ products appear at $99 and should not be treated as a low-cost semaglutide or tirzepatide tier. Other catalog items include hormone-related care, sermorelin, MIC with B12, and sexual-health treatment. Keep any proposed additional product itemized, with its own clinical rationale, rather than letting a broad starting-price banner define the medication budget.

The service has also advertised dissolving oral GLP-1 tablets and microdose injections. Those categories require their own prescription and quote. A lower-dose program or a needle-free form does not automatically provide equivalent treatment at a lower cost. Ask the clinician which preparation is proposed and why. In particular, a compounded tablet should not inherit the approval, labeling, or trial results of an approved branded oral medication merely because the ingredient or administration route sounds familiar.

Identify the company before sharing a history

The public legal information does not clearly identify an operating entity or street address. That leaves a basic accountability question unresolved even where prices are readable. Ask for the seller's legal name, the medical practice, the assigned clinician, and the pharmacy dispensing the prescription. These are different roles, and a banner about licensed or board-certified physicians cannot identify all of them. A clear answer should establish who provides care, who supplies medication, and who collects payment.

Zera claims 50-state availability through a banner rather than a complete service-area list. Confirm the proposed prescription and clinician arrangement in your location. The company also uses FDA-regulated pharmacy language, which does not mean its compounded medications are FDA approved. Obtain the formulation, concentration, quantity, storage, and written instructions for the actual product. A facility-related claim does not establish equivalence to a branded medicine or predict a particular patient's response.

Resolve the terms that follow the first order

Ask how follow-up is arranged, how medication changes affect the bill, and what stops the next charge. Cancellation and refunds need to be explained for the selected monthly or quarterly plan, including medication already prepared. The service's public material does not provide substantive pregnancy, breastfeeding, or postpartum guidance. If relevant, discuss those circumstances and coordination with existing clinicians before choosing treatment; a wide catalog does not establish maternal specialty experience.

Zera may interest someone seeking several formulation choices, but its missing business identity and varied starting-price presentation complicate the decision. Use $179 semaglutide and $255 tirzepatide as published monthly-plan information, with the actual prescription still confirmed individually. Keep the quarterly tirzepatide offer and introductory floors separate. A satisfactory choice requires a complete recurring quote and identifiable care partners, not simply a low figure repeated in a general promotional banner.